Aller au contenu

Publications scientifiques

  • article Silva LFL, Scholl JN, Weber AF, Dias CK, Pizzato PR, Lima VP, Sévigny J, Battastini AMO, Figueiró F

    Assessing the impact of CD73 inhibition on overcoming anti-EGFR resistance in glioma cells

    Oncol Res 33 (4), 2025.

    DOI PUBMED
  • article Manica FM, Campesato LFI, Scholl JN, Braganhol E, Bergamin LS, Edelweiss MIA, Lenz G, Sevigny J, Figueiró F, Battastini AMO

    Assessing Ecto-5′-Nucleotidase/CD73 Expression and Malignancy Parameters in Early- and Late- Passage C6 Glioma Cells

    Neurochem Res 50 (3), 2025.

    DOI PUBMED
  • article Bi C, Mirza S, Baburi H, Schäkel L, Winzer R, Moschütz S, Keetz K, Lopez V, Pelletier J, Sévigny J, Schulze Zur Wiesch J, Claff T, Tolosa E, Namasivayam V, Sträter N, Müller CE

    Synthesis, Characterization, Interactions, and Immunomodulatory Function of Ectonucleotidase CD39/CD73 Inhibitor 8-Butylthioadenosine 5′-Monophosphate

    ACS Pharmacol Transl Sci 8 (5), 2025.

    DOI PUBMED
  • article da Silva ÁC, Scholl JN, de Fraga Dias A, Weber AF, Morrone FB, Cruz-López O, Conejo-García A, Campos JM, Sévigny J, Figueiró F, Battastini AMO

    Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme

    Purinergic Signal 21 (1), 2025.

    DOI PUBMED
  • article Rodríguez-Martínez A, Torrejón-Escribano B, Eritja N, Dorca-Arévalo J, Gabaldón C, Sévigny J, Matias-Guiu X, Martín-Satué M

    Endometrial epithelial cell organoids as tools for studying the CD39 family of enzymes and for validating enzyme inhibitors

    Histol Histopathol 40 (2), 2025.

    DOI PUBMED
  • article Babou Kammoe RB, Sévigny J

    Extracellular nucleotides in smooth muscle contraction

    Biochem Pharmacol 220 2024.

    DOI PUBMED
  • article Wu X, Chen PI, Whitener RL, MacDougall MS, Coykendall VMN, Yan H, Kim YB, Harper W, Pathak S, Iliopoulou BP, Hestor A, Saunders DC, Spears E, Sévigny J, Maahs DM, Basina M, Sharp SA, Gloyn AL, Powers AC, Kim SK, Jensen KP, Meyer EH

    CD39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets

    Front Immunol 15 2024.

    DOI PUBMED
  • article Tasleem M, Pelletier J, Sévigny J, Hussain Z, Khan A, Al-Harrasi A, El-Kott AF, Taslimi P, Negm S, Shafiq Z, Iqbal J

    Synthesis, in vitro, and in silico studies of morpholine-based thiosemicarbazones as ectonucleotide pyrophosphatase/phosphodiesterase-1 and -3 inhibitors

    Int J Biol Macromol 266 (Pt 2), 2024.

    DOI PUBMED
  • article Alzahrani AYA, Hameed A, Khan AR, Pelletier J, Sévigny J, Iqbal J

    Design, synthesis and in vitro evaluation of novel sulfonylurea and sulfonylthiourea as ectonucleotidases inhibitors

    Results in Chemistry 7 (101548), 2024.

    DOI
  • article Iqbal J, Bano S, Khan IA, Sévigny J, Huang Q

    Ectonucleotidase inhibitors: an updated patent review (2017-2023)

    Expert Opin Ther Pat 34 (11), 2024.

    DOI PUBMED
  • article Favre J, Roy C, Guihot AL, Drouin A, Laprise M, Gillis MA, Robson SC, Thorin E, Sévigny J, Henrion D, Kauffenstein G

    NTPDase1/CD39 Ectonucleotidase Is Necessary for Normal Arterial Diameter Adaptation to Flow

    Int J Mol Sci 24 (20), 2023.

    DOI PUBMED
  • article Khan Jadoon MS, Pelletier J, Sévigny J, Iqbal J

    Synthesis of new class of indole acetic acid sulfonate derivatives as ectonucleotidases inhibitors

    RSC Adv 13 (42), 2023.

    DOI PUBMED